|
FDA Should Raise Review Issues Earlier, Sponsors Say
Drugmakers are urging the FDA to raise drug review issues with sponsors earlier, as one company says its recent complete response letter came after a frustrating lack of communication from the agency.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives